Results 91 to 100 of about 4,490 (182)

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model

, 2018
Purpose: Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (NTRK1) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer.
Noritaka Furuya, Azusa Tanimoto, Rong Wang, Takayoshi Kinoshita, Sachiko Arai, Seiji Yano, Akihiro Nishiyama, Atsushi Tajima, Koji Fukuda, Kenji Kita, Shoichiro Tange, Tadaaki Yamada, Shinji Takeuchi   +12 more
core   +1 more source

ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report

Frontiers in Cardiovascular Medicine
BackgroundEntrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease.
Qi Yujuan, Qi Yujuan, Ma Xiaozhong, Ma Xiaozhong, Wu Zhenhua, Wu Zhenhua, Bai Yunpeng, Bai Yunpeng   +7 more
doaj   +1 more source

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu   +12 more
doaj   +1 more source

A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma

Current Oncology
We present a case of a lung adenocarcinoma patient harboring a novel kinesin family member 5B (KIF5B)-NTRK1 gene fusion that responds well to entrectinib.
Hui Li, Huicong Liu, Lisha Xiao, Huabin Gao, Huiting Wei, Anjia Han, Gengpeng Lin   +6 more
doaj   +1 more source

Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review

Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1-positive metastatic non-small cell lung cancer (NSCLC).
Yamamoto, Takanori, Hashimoto, Takahiko, Nakashima, Kuniya, Ishii, Makoto, Tanaka, Akihito, Futamura, Keisuke, Sakai, Yoshinori, Okachi, Shotaro, Ushijima, Futoshi, Shibata, Hirofumi, Numaguchi, Atsushi, Ito, Katsuki, Hase, Tetsunari, Inden, Yasuya   +13 more
core  

PREPARATION AND EVALUATION OF ENTRECTINIB PLGA NANOBUBBLES BY CENTRAL COMPOSITE DESIGN

Objective: For targeted delivery of entrectinib, we created nanobubbles with a poly(lactic-co-glycolic acid) (PLGA) shell and a perfluoropentane core. Methods: Entrectinib was encapsulated in PLGA nanobubbles by a modified W/O/W double emulsion, solvent ...
BHIKSHAPATHI, D. V. R. N., NANDINI, P.
core  

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

Lung Cancer: Targets and Therapy, 2019
Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel +
Facchinetti F, Friboulet L
doaj  

Entrectinib [PDF]

, 2020
openaire   +1 more source

Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER. [PDF]

PLoS One
Yang J, Liu J, Zhao G, Li H, Sun G.
europepmc   +1 more source

Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. [PDF]

Cancer Res Commun
Contreras-Zárate MJ, Jaramillo-Gómez JA, Marquez-Ortiz RA, Pham TC, Koliavas SN, Ormond DR, Navarro AC, Nemenoff RA, Camidge DR, Cittelly DM.   +9 more
europepmc   +1 more source